Overview

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

Status:
Recruiting
Trial end date:
2024-11-25
Target enrollment:
Participant gender:
Summary
This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Collaborator:
Astellas Pharma Inc
Treatments:
Talazoparib